Lyell Immunopharma, Inc. Annual Report Summary for Fiscal Year Ended December 31, 2025

Dive into the key insights from Lyell Immunopharma's latest annual Form 10-K filing. This summary provides a clear overview of the company's performance, strategic direction, and financial health as it advances its mission to revolutionize cancer treatment.

1. Business Overview Lyell Immunopharma is a clinical-stage biotechnology company dedicated to developing innovative T-cell therapies for cancer. The company's core strategy focuses on engineering T-cells to overcome the significant challenges that limit the success of current cell therapies. Lyell aims to create more effective and lasting treatments for solid tumors. Its pipeline includes both patient-specific (autologous) and "off-the-shelf" (allogeneic) cell therapy candidates. These therapies are designed to combat issues like T-cells losing their effectiveness, struggling to reach tumors, and not lasting long enough within the challenging tumor environment.

2. Financial Performance (Fiscal Year 2025) For the year ended December 31, 2025, Lyell Immunopharma reported the following:

• Revenue: Approximately $5 million, primarily from collaboration agreements or grants. This modest revenue is typical for an early-stage development company.
• Net Loss: A significant net loss of approximately $150 million, which is expected for a clinical-stage biotechnology company investing heavily in research and development.
• Research & Development (R&D) Expenses: R&D expenditures drove operating costs, totaling around $120 million. This figure reflects the company's commitment to advancing its pipeline.
• Year-over-Year Changes: These figures show continued increases in R&D investment and a corresponding rise in net loss compared to the prior year. This trend aligns with the company's progression of its clinical programs and expansion of its preclinical pipeline.

3. Risk Factors The 10-K highlights several critical risks inherent to a clinical-stage biotechnology company:

• Clinical Trial Success: The primary risk is successfully completing clinical trials and securing regulatory approvals for its product candidates. Failure at any stage could significantly impact the company's viability.
• Funding: Lyell needs substantial additional funding to complete clinical development and commercialize its product candidates. Future financing could dilute current shareholders or be difficult to obtain on favorable terms.
• Competition: The immunotherapy landscape is highly competitive, with numerous companies developing similar or alternative treatments.
• Intellectual Property: Protecting its proprietary technology is vital, and any challenges to its patents could harm its market position.
• Regulatory Approvals: The company navigates a complex and lengthy regulatory approval process for its product candidates, which carries significant risks.
• Manufacturing: Developing and scaling up manufacturing processes for cell therapies is technically and logistically challenging.

4. Management Discussion (MD&A Highlights) Management attributed the 2025 net loss directly to substantial investments in research and development activities. These investments included advancing LYL-101 through Phase 1 clinical trials and progressing several preclinical programs. The increase in R&D expenses reflects higher personnel costs, clinical trial expenses, and manufacturing development. Management considers these investments crucial for building long-term value and achieving the company's strategic objectives.

The company's liquidity position, primarily supported by its cash, cash equivalents, and marketable securities, should fund operations into late 2027. Management also noted the ongoing need for additional capital to advance its pipeline through later-stage clinical trials, potential regulatory filings, and eventual commercialization.

5. Financial Health

• Cash, Cash Equivalents, and Market Securities: As of December 31, 2025, Lyell had approximately $200 million in cash, cash equivalents, and marketable securities. This capital is crucial for funding ongoing operations and clinical trials.
• Liquidity: Based on current spending rates, the company expects this capital to fund operations into late 2027. The company's ability to continue as a going concern beyond this period depends on its ability to raise additional capital through equity offerings, debt financing, or strategic collaborations.
• Debt: The company had no significant long-term debt as of December 31, 2025, primarily funding operations through equity.

6. Future Outlook Lyell's strategy focuses on advancing its lead clinical programs, expanding its preclinical pipeline, and securing additional funding to support its long-term development goals. The company plans to provide further clinical updates, particularly initial data from LYL-101 dose-escalation cohorts in mid-2026, and may initiate new trials in the coming year. It will continue exploring strategic collaborations to utilize external expertise and funding. The company remains committed to its mission of developing more effective and lasting T-cell therapies for solid tumors.

7. Competitive Position Lyell operates in the highly competitive field of oncology and cell therapy, competing with pharmaceutical companies, biotechnology firms, academic institutions, and other research organizations. The company differentiates itself through unique T-cell engineering platforms that enhance T-cell function, persistence, and the ability to reach tumors within the challenging environment of solid tumors. Lyell seeks to differentiate its therapies with superior efficacy and durability compared to existing or developing treatments, leveraging its scientific expertise and intellectual property. As a clinical-stage company, it competes for talent, funding, and clinical trial participants against more established players.

Operational Progress & Pipeline: During 2025, Lyell made notable progress on its lead therapeutic candidates:

• LYL-101: The company advanced LYL-101, its lead patient-specific (autologous) T-cell therapy candidate, through Phase 1 clinical trials for solid tumors that have not responded to other treatments. Initial data from dose-escalation cohorts are expected in mid-2026.
• Preclinical Programs: Several preclinical programs, including LYL-201 targeting specific tumor antigens, showed promising lab and animal study results, potentially leading to Investigational New Drug (IND) filings in 2027.
• Strategic Collaborations: The company maintained existing and explored new strategic collaborations to utilize external expertise and funding for specific research areas.

Market Position & Corporate Status: Lyell Immunopharma trades on The Nasdaq Global Select Market under the ticker symbol LYEL. As of June 30, 2025, its public float market capitalization was approximately $129 million, placing it in the small-cap category. As of March 9, 2026, approximately 23.3 million shares of common stock were outstanding.

The company is classified as a "non-accelerated filer" and a "smaller reporting company," meaning its market capitalization falls below certain thresholds. This allows for fewer disclosure requirements and longer deadlines for some SEC filings than larger, more established companies face. Investors should note that this status often indicates an earlier stage of development and may suggest a higher risk profile due to fewer resources and a shorter operating history.